Talk to us
Developing Cell-Derived Nano-Ghost for Targeted Combined Therapy of Metastatic Cancer

Developing Cell-Derived Nano-Ghost for Targeted Combined Therapy of Metastatic Cancer

22|November|2017 - 2|February|2022
Developing Cell-Derived Nano-Ghost for Targeted Combined Therapy of Metastatic Cancer
https://technion.zoom.us/j/94516232920

Metastasis is the major cause of treatment failure and mortality. The main goal of this study was to develop a natural targeted delivery platform—termed Nano-Ghosts that will target metastatic cancer while delivering different therapeutics. The NGs are nano-vesicles reconstructed from the cytoplasmic membranes of allogeneic human mesenchymal stem cells (MSC). The NGs’ retention of MSC membrane proteins ensures their safety and allogenic tolerability and furnishes them with the ability to home in on multiple tumors. I will first demonstrated that the NGs selectively accumulated in the lungs of metastases-bearing mice. Next, I will present that NG loaded with soluble TRAIL protein or a pDNA encoding the same protein (pTRAIL) promoted apoptosis in metastatic cancer cells. Furthermore, efficacy studies in a metastatic NSCLC model demonstrated over 70% tumor growth inhibition of established metastases

 

Abstract

Share this:
There is no second chance for a first impression
We will be happy to update you ahead of the upcoming open day for a bachelor’s degree
  • This field is for validation purposes and should be left unchanged.